SCHEMBL880204

SCHEMBL880204

CC(=O)OC1CC=CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20237060 0.86
SCHEMBL28115386 0.84 TSHR (0.35)
SCHEMBL4283399 0.84 CHRM2 (0.33)
SCHEMBL7640695 0.84 TSHR (0.35)
SCHEMBL28114860 0.84 TSHR (0.35)
SCHEMBL3672565 0.83 CHRM2 (0.33)
SCHEMBL10778204 0.81 CHRM2 (0.42)
SCHEMBL10929532 0.81 CHRM2 (0.42)
SCHEMBL3678402 0.81 EPHX1 (0.34)
SCHEMBL3678399 0.81 EPHX1 (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108976230-A A method of dolasetron mesilate key intermediate is prepared based on graphene activation 东莞市联洲知识产权运营管理有限公司 2018-12-11 CN claimed
CN-105566840-A Method for preparing acrylonitrile-butadiene-styrene dispersoid WANG JINMING 2016-05-11 CN claimed
CN-108976230-A A method of dolasetron mesilate key intermediate is prepared based on graphene activation 东莞市联洲知识产权运营管理有限公司 2018-12-11 CN disclosed
CN-108976230-A A method of dolasetron mesilate key intermediate is prepared based on graphene activation 东莞市联洲知识产权运营管理有限公司 2018-12-11 CN disclosed
CN-105566840-A Method for preparing acrylonitrile-butadiene-styrene dispersoid WANG JINMING 2016-05-11 CN disclosed
US-8809264-B2 Quinoxalinyl macrocyclic hepatitis C virus serine protease inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2014-08-19 US disclosed
US-8361958-B2 Oximyl HCV serine protease inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2013-01-29 US disclosed
EP-2433941-A1 Process for isolating the antiviral agent [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one Bristol-Myers Squibb Company (US) 2012-03-28 EP disclosed
US-8101567-B2 Heteroaryl-containing tripeptide HCV serine protease inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2012-01-24 US disclosed
US-7723423-B2 Gas-barrier resin composition CRYOVAC, INC. (US) 2010-05-25 US disclosed
US-7635683-B2 Quinoxalinyl tripeptide hepatitis C virus inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2009-12-22 US disclosed
US-20070299078-A1 Quinoxalinyl Macrocyclic Hepatitis C Virus Serine Protease Inhibitors ENANTA PHARMACEUTICALS, INC. 2007-12-27 US disclosed
US-7285598-B2 Polymer and process for producing the same KURARAY CO., LTD. (JP) 2007-10-23 US disclosed
US-20070093599-A1 Gas-barrier resin composition CRYOVAC, INC. (US) 2007-04-26 US disclosed
US-20070021556-A1 Gas-barrier resin composition KURARAY CO. LTD. (JP) 2007-01-25 US disclosed
EP-1746131-A2 Gas-barrier resin composition Cryovac, Inc. (US) 2007-01-24 EP disclosed
US-20060149009-A1 Produced by ring-opening, in the presence of a metal alkylidene complex comprising a ligand with an imidazolidine structure, a cyclic olefin comprising at least one cyclic olefin further comprising a hydroxy group or a functional group that can be converted into a hydroxy group, and hydrogenating KURARAY CO., LTD. (JP) 2006-07-06 US disclosed
US-6559241-B2 Process for producing a hydrogenated polymer KURARAY CO., LTD. (JP) 2003-05-06 US disclosed
US-20020137854-A1 Process for producing a hydrogenated polymer KURARAY CO. LTD. (JP) 2002-09-26 US disclosed
EP-1241189-A1 Process for producing a hydrogenated polymer KURARAY CO., LTD. (JP) 2002-09-18 EP disclosed